Cancer

The most clinically effective treatments for cancer are focused on targeting and activating NK cells. Activation of NK Cells is required to kill cancer cells.

Activation of NK cells requires multiple signals, which typically come from the cancer cell and result in cell-to-cell contact. Once connected, activated NK cells lyse (kill) tumor cells.

In certain cancers, and in cancer relapse, the NK Cells are not activated. INKmune is an innovative biologic delivery system that primes the patients own resting NK Cells to target and kill cancer cells.

We are currently evaluating INKmune in one clinical trial:

The CaRe Prostate study is a Phase l/ll trial in patients with metastatic Castrate resistant prostate cancer.Click HERE to learn more